U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C9H13N
Molecular Weight 135.2062
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DEXTROAMPHETAMINE

SMILES

C[C@H](N)CC1=CC=CC=C1

InChI

InChIKey=KWTSXDURSIMDCE-QMMMGPOBSA-N
InChI=1S/C9H13N/c1-8(10)7-9-5-3-2-4-6-9/h2-6,8H,7,10H2,1H3/t8-/m0/s1

HIDE SMILES / InChI

Molecular Formula C9H13N
Molecular Weight 135.2062
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021977lbl.pdf | https://www.drugs.com/ppa/lisdexamfetamine.html | https://www.ncbi.nlm.nih.gov/pubmed/27125257

Lisdexamfetamine (LDX) is a d-amphetamine (d-AMPH) pro-drug used to treat Attention Deficit and Hyperactivity Disorder (ADHD) and Binge Eating Disorder (BED). After oral administration, lisdexamfetamine dimesylate is rapidly absorbed from the gastrointestinal tract and converted to dextroamphetamine, which is responsible for the drug’s activity. Amphetamines are thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal space. Most common adverse reactions in children, adolescents and/or adults with ADHD were anorexia, anxiety, decreased appetite, decreased weight, diarrhea, dizziness, dry mouth, irritability, insomnia, nausea, upper abdominal pain, and vomiting. Agents that alter urinary pH can alter blood levels of amphetamine. Acidifying agents decrease amphetamine blood levels, while alkalinizing agents increase amphetamine blood levels. Needs to adjust Lisdexamfetamine dosage accordingly.

Originator

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
VYVANSE

Approved Use

VYVANSE® is indicated for the treatment of: Attention Deficit Hyperactivity Disorder (ADHD) [see Clinical Studies (14.1)

Launch Date

1.17218882E12
Primary
VYVANSE

Approved Use

VYVANSE® is indicated for the treatment of: Attention Deficit Hyperactivity Disorder (ADHD) [see Clinical Studies (14.1)

Launch Date

1.17218882E12
Primary
DEXEDRINE

Approved Use

Narcolepsy. Attention Deficit Disorder with Hyperactivity. As an integral part of a total treatment program that typically includes other measures (psychological, educational, social) for patients (ages 6 years to 16 years) with this syndrome. A diagnosis of Attention Deficit Hyperactivity Disorder (ADHD; DSM-IV) implies the presence of the hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. The symptoms must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and be present in 2 or more settings, e.g., school (or work) and at home. The symptoms must not be better accounted for by another mental disorder. For the Inattentive Type, at least 6 of the following symptoms must have persisted for at least 6 months: lack of attention to details/careless mistakes; lack of sustained attention; poor listener; failure to follow through on tasks; poor organization; avoids tasks requiring sustained mental effort; loses things; easily distracted; forgetful. For the Hyperactive-Impulsive Type, at least 6 of the following symptoms must have persisted for at least 6 months: fidgeting/squirming; leaving seat; inappropriate running/climbing; difficulty with quiet activities; “on the go”; excessive talking; blurting answers; can't wait turn; intrusive. The Combined Type requires both inattentive and hyperactive-impulsive criteria to be met.

Launch Date

3.15532804E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
47.9 ng/mL
70 mg 1 times / day multiple, oral
dose: 70 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LISDEXAMFETAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
24.7 ng/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXTROAMPHETAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
36.6 ng/mL
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXTROAMPHETAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
60.7 ng × h/mL
70 mg 1 times / day multiple, oral
dose: 70 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LISDEXAMFETAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
431 ng × h/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXTROAMPHETAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
12 h
70 mg 1 times / day multiple, oral
dose: 70 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LISDEXAMFETAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
12.1 h
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXTROAMPHETAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
12 h
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXTROAMPHETAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
70 mg 1 times / day multiple, oral (max)
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources: Page: p.8
unhealthy, 13 - 17
n = 233
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Age Group: 13 - 17
Sex: M+F
Population Size: 233
Sources: Page: p.8
Disc. AE: Irritability, Decreased appetite...
AEs leading to
discontinuation/dose reduction:
Irritability (1.3%)
Decreased appetite (0.86%)
Insomnia (0.86%)
Sources: Page: p.8
1200 mg single, oral
Overdose
Dose: 1200 mg
Route: oral
Route: single
Dose: 1200 mg
Sources: Page: e771
healthy, 17
n = 1
Health Status: healthy
Age Group: 17
Sex: F
Population Size: 1
Sources: Page: e771
Disc. AE: Delirium, Tachycardia...
AEs leading to
discontinuation/dose reduction:
Delirium (acute)
Tachycardia
Hypertension
Tachypnea
Creatine kinase increased (mild)
Sources: Page: e771
70 mg 1 times / day multiple, oral (max)
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources: Page: p.8
unhealthy, 18 - 55
n = 358
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Age Group: 18 - 55
Sex: M+F
Population Size: 358
Sources: Page: p.8
Disc. AE: Insomnia, Tachycardia...
AEs leading to
discontinuation/dose reduction:
Insomnia (2%)
Tachycardia (1%)
Irritability (1%)
Hypertension (1%)
Headache (1%)
Anxiety (1%)
Dyspnea (1%)
Sources: Page: p.8
70 mg 1 times / day multiple, oral (max)
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources: Page: p.8
unhealthy, 6 - 12
n = 218
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Age Group: 6 - 12
Sex: M+F
Population Size: 218
Sources: Page: p.8
Disc. AE: Ventricular hypertrophy, Tic...
AEs leading to
discontinuation/dose reduction:
Ventricular hypertrophy (1%)
Tic (1%)
Vomiting (1%)
Psychomotor hyperactivity (1%)
Insomnia (1%)
Rash (1%)
Sources: Page: p.8
30 mg 1 times / day steady, oral
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, adolescents
n = 78
Health Status: unhealthy
Condition: Attention-Deficit/Hyperactivity Disorder
Age Group: adolescents
Population Size: 78
Sources:
Other AEs: Decreased appetite, Insomnia...
Other AEs:
Decreased appetite (below serious, 29 patients)
Insomnia (below serious, 7 patients)
Weight decreased (below serious, 3 patients)
Irritability (below serious, 6 patients)
Fatigue (below serious, 4 patients)
Nasopharyngitis (below serious, 2 patients)
Sources:
20 mg single, oral
Dose: 20 mg
Route: oral
Route: single
Dose: 20 mg
Sources:
healthy, adult
n = 27
Health Status: healthy
Condition: Acute Sleep Loss
Age Group: adult
Sex: M
Population Size: 27
Sources:
Other AEs: Nausea...
Other AEs:
Nausea (below serious, 1 patient)
Sources:
50 mg single, oral
Dose: 50 mg
Route: oral
Route: single
Dose: 50 mg
Sources:
healthy, adult
n = 27
Health Status: healthy
Condition: Acute Sleep Loss
Age Group: adult
Sex: M
Population Size: 27
Sources:
Other AEs: Headache, Nausea...
Other AEs:
Headache (below serious, 4 patients)
Nausea (below serious, 1 patient)
Vomiting (below serious, 2 patients)
Sources:
70 mg single, oral
Dose: 70 mg
Route: oral
Route: single
Dose: 70 mg
Sources:
healthy, adult
n = 27
Health Status: healthy
Condition: Acute Sleep Loss
Age Group: adult
Sex: M
Population Size: 27
Sources:
Other AEs: Headache, Nausea...
Other AEs:
Headache (below serious, 2 patients)
Nausea (below serious, 2 patients)
Sources:
70 mg 1 times / day steady, oral (max)
Dose: 70 mg, 1 times / day
Route: oral
Route: steady
Dose: 70 mg, 1 times / day
Sources:
unhealthy, adult
n = 79
Health Status: unhealthy
Condition: Attention-Deficit/Hyperactivity Disorder
Age Group: adult
Population Size: 79
Sources:
Other AEs: Diarrhea, Dry mouth...
Other AEs:
Diarrhea (below serious, 6 patients)
Dry mouth (below serious, 25 patients)
Fatigue (below serious, 6 patients)
Feeling jittery (below serious, 10 patients)
Irritability (below serious, 8 patients)
Upper respiratory tract infection (below serious, 5 patients)
Heart rate increased (below serious, 4 patients)
Weight decreased (below serious, 8 patients)
Anorexia (below serious, 4 patients)
Decreased appetite (below serious, 26 patients)
Headache (below serious, 20 patients)
Initial insomnia (below serious, 8 patients)
Insomnia (below serious, 10 patients)
Libido decreased (below serious, 4 patients)
Hyperhidrosis (below serious, 5 patients)
Sources:
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder|Binge Eating Disorder
Sources: Page: p.1
Disc. AE: Abuse, Dependence...
AEs leading to
discontinuation/dose reduction:
Abuse
Dependence
Cardiovascular disorder (NOS) (grade 3-5)
Stroke (serious)
Myocardial infarction (serious)
Blood pressure increased
Heart rate increased
Psychiatric symptom NOS
Psychotic symptom
Manic symptom
Growth suppression
Vascular disorders
Raynaud's phenomenon
Serotonin syndrome
Sources: Page: p.1
50 mg 1 times / day steady, oral (max)
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy
n = 28
Health Status: unhealthy
Condition: Major Depressive Disorder
Population Size: 28
Sources:
Other AEs: Decreased appetite, Dry mouth...
Other AEs:
Decreased appetite (below serious, 8 patients)
Dry mouth (below serious, 7 patients)
Insomnia (below serious, 10 patients)
Irritability (below serious, 3 patients)
Diaphoresis (below serious, 2 patients)
Libido decreased (below serious, 2 patients)
Tinnitus (below serious, 2 patients)
Muscle tension (below serious, 4 patients)
Tachycardia (below serious, 3 patients)
Paresthesia (below serious, 2 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Decreased appetite 0.86%
Disc. AE
70 mg 1 times / day multiple, oral (max)
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources: Page: p.8
unhealthy, 13 - 17
n = 233
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Age Group: 13 - 17
Sex: M+F
Population Size: 233
Sources: Page: p.8
Insomnia 0.86%
Disc. AE
70 mg 1 times / day multiple, oral (max)
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources: Page: p.8
unhealthy, 13 - 17
n = 233
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Age Group: 13 - 17
Sex: M+F
Population Size: 233
Sources: Page: p.8
Irritability 1.3%
Disc. AE
70 mg 1 times / day multiple, oral (max)
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources: Page: p.8
unhealthy, 13 - 17
n = 233
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Age Group: 13 - 17
Sex: M+F
Population Size: 233
Sources: Page: p.8
Hypertension Disc. AE
1200 mg single, oral
Overdose
Dose: 1200 mg
Route: oral
Route: single
Dose: 1200 mg
Sources: Page: e771
healthy, 17
n = 1
Health Status: healthy
Age Group: 17
Sex: F
Population Size: 1
Sources: Page: e771
Tachycardia Disc. AE
1200 mg single, oral
Overdose
Dose: 1200 mg
Route: oral
Route: single
Dose: 1200 mg
Sources: Page: e771
healthy, 17
n = 1
Health Status: healthy
Age Group: 17
Sex: F
Population Size: 1
Sources: Page: e771
Tachypnea Disc. AE
1200 mg single, oral
Overdose
Dose: 1200 mg
Route: oral
Route: single
Dose: 1200 mg
Sources: Page: e771
healthy, 17
n = 1
Health Status: healthy
Age Group: 17
Sex: F
Population Size: 1
Sources: Page: e771
Delirium acute
Disc. AE
1200 mg single, oral
Overdose
Dose: 1200 mg
Route: oral
Route: single
Dose: 1200 mg
Sources: Page: e771
healthy, 17
n = 1
Health Status: healthy
Age Group: 17
Sex: F
Population Size: 1
Sources: Page: e771
Creatine kinase increased mild
Disc. AE
1200 mg single, oral
Overdose
Dose: 1200 mg
Route: oral
Route: single
Dose: 1200 mg
Sources: Page: e771
healthy, 17
n = 1
Health Status: healthy
Age Group: 17
Sex: F
Population Size: 1
Sources: Page: e771
Anxiety 1%
Disc. AE
70 mg 1 times / day multiple, oral (max)
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources: Page: p.8
unhealthy, 18 - 55
n = 358
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Age Group: 18 - 55
Sex: M+F
Population Size: 358
Sources: Page: p.8
Dyspnea 1%
Disc. AE
70 mg 1 times / day multiple, oral (max)
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources: Page: p.8
unhealthy, 18 - 55
n = 358
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Age Group: 18 - 55
Sex: M+F
Population Size: 358
Sources: Page: p.8
Headache 1%
Disc. AE
70 mg 1 times / day multiple, oral (max)
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources: Page: p.8
unhealthy, 18 - 55
n = 358
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Age Group: 18 - 55
Sex: M+F
Population Size: 358
Sources: Page: p.8
Hypertension 1%
Disc. AE
70 mg 1 times / day multiple, oral (max)
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources: Page: p.8
unhealthy, 18 - 55
n = 358
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Age Group: 18 - 55
Sex: M+F
Population Size: 358
Sources: Page: p.8
Irritability 1%
Disc. AE
70 mg 1 times / day multiple, oral (max)
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources: Page: p.8
unhealthy, 18 - 55
n = 358
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Age Group: 18 - 55
Sex: M+F
Population Size: 358
Sources: Page: p.8
Tachycardia 1%
Disc. AE
70 mg 1 times / day multiple, oral (max)
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources: Page: p.8
unhealthy, 18 - 55
n = 358
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Age Group: 18 - 55
Sex: M+F
Population Size: 358
Sources: Page: p.8
Insomnia 2%
Disc. AE
70 mg 1 times / day multiple, oral (max)
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources: Page: p.8
unhealthy, 18 - 55
n = 358
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Age Group: 18 - 55
Sex: M+F
Population Size: 358
Sources: Page: p.8
Insomnia 1%
Disc. AE
70 mg 1 times / day multiple, oral (max)
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources: Page: p.8
unhealthy, 6 - 12
n = 218
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Age Group: 6 - 12
Sex: M+F
Population Size: 218
Sources: Page: p.8
Psychomotor hyperactivity 1%
Disc. AE
70 mg 1 times / day multiple, oral (max)
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources: Page: p.8
unhealthy, 6 - 12
n = 218
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Age Group: 6 - 12
Sex: M+F
Population Size: 218
Sources: Page: p.8
Rash 1%
Disc. AE
70 mg 1 times / day multiple, oral (max)
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources: Page: p.8
unhealthy, 6 - 12
n = 218
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Age Group: 6 - 12
Sex: M+F
Population Size: 218
Sources: Page: p.8
Tic 1%
Disc. AE
70 mg 1 times / day multiple, oral (max)
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources: Page: p.8
unhealthy, 6 - 12
n = 218
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Age Group: 6 - 12
Sex: M+F
Population Size: 218
Sources: Page: p.8
Ventricular hypertrophy 1%
Disc. AE
70 mg 1 times / day multiple, oral (max)
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources: Page: p.8
unhealthy, 6 - 12
n = 218
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Age Group: 6 - 12
Sex: M+F
Population Size: 218
Sources: Page: p.8
Vomiting 1%
Disc. AE
70 mg 1 times / day multiple, oral (max)
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources: Page: p.8
unhealthy, 6 - 12
n = 218
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Age Group: 6 - 12
Sex: M+F
Population Size: 218
Sources: Page: p.8
Nasopharyngitis below serious, 2 patients
30 mg 1 times / day steady, oral
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, adolescents
n = 78
Health Status: unhealthy
Condition: Attention-Deficit/Hyperactivity Disorder
Age Group: adolescents
Population Size: 78
Sources:
Decreased appetite below serious, 29 patients
30 mg 1 times / day steady, oral
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, adolescents
n = 78
Health Status: unhealthy
Condition: Attention-Deficit/Hyperactivity Disorder
Age Group: adolescents
Population Size: 78
Sources:
Weight decreased below serious, 3 patients
30 mg 1 times / day steady, oral
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, adolescents
n = 78
Health Status: unhealthy
Condition: Attention-Deficit/Hyperactivity Disorder
Age Group: adolescents
Population Size: 78
Sources:
Fatigue below serious, 4 patients
30 mg 1 times / day steady, oral
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, adolescents
n = 78
Health Status: unhealthy
Condition: Attention-Deficit/Hyperactivity Disorder
Age Group: adolescents
Population Size: 78
Sources:
Irritability below serious, 6 patients
30 mg 1 times / day steady, oral
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, adolescents
n = 78
Health Status: unhealthy
Condition: Attention-Deficit/Hyperactivity Disorder
Age Group: adolescents
Population Size: 78
Sources:
Insomnia below serious, 7 patients
30 mg 1 times / day steady, oral
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, adolescents
n = 78
Health Status: unhealthy
Condition: Attention-Deficit/Hyperactivity Disorder
Age Group: adolescents
Population Size: 78
Sources:
Nausea below serious, 1 patient
20 mg single, oral
Dose: 20 mg
Route: oral
Route: single
Dose: 20 mg
Sources:
healthy, adult
n = 27
Health Status: healthy
Condition: Acute Sleep Loss
Age Group: adult
Sex: M
Population Size: 27
Sources:
Nausea below serious, 1 patient
50 mg single, oral
Dose: 50 mg
Route: oral
Route: single
Dose: 50 mg
Sources:
healthy, adult
n = 27
Health Status: healthy
Condition: Acute Sleep Loss
Age Group: adult
Sex: M
Population Size: 27
Sources:
Vomiting below serious, 2 patients
50 mg single, oral
Dose: 50 mg
Route: oral
Route: single
Dose: 50 mg
Sources:
healthy, adult
n = 27
Health Status: healthy
Condition: Acute Sleep Loss
Age Group: adult
Sex: M
Population Size: 27
Sources:
Headache below serious, 4 patients
50 mg single, oral
Dose: 50 mg
Route: oral
Route: single
Dose: 50 mg
Sources:
healthy, adult
n = 27
Health Status: healthy
Condition: Acute Sleep Loss
Age Group: adult
Sex: M
Population Size: 27
Sources:
Headache below serious, 2 patients
70 mg single, oral
Dose: 70 mg
Route: oral
Route: single
Dose: 70 mg
Sources:
healthy, adult
n = 27
Health Status: healthy
Condition: Acute Sleep Loss
Age Group: adult
Sex: M
Population Size: 27
Sources:
Nausea below serious, 2 patients
70 mg single, oral
Dose: 70 mg
Route: oral
Route: single
Dose: 70 mg
Sources:
healthy, adult
n = 27
Health Status: healthy
Condition: Acute Sleep Loss
Age Group: adult
Sex: M
Population Size: 27
Sources:
Feeling jittery below serious, 10 patients
70 mg 1 times / day steady, oral (max)
Dose: 70 mg, 1 times / day
Route: oral
Route: steady
Dose: 70 mg, 1 times / day
Sources:
unhealthy, adult
n = 79
Health Status: unhealthy
Condition: Attention-Deficit/Hyperactivity Disorder
Age Group: adult
Population Size: 79
Sources:
Insomnia below serious, 10 patients
70 mg 1 times / day steady, oral (max)
Dose: 70 mg, 1 times / day
Route: oral
Route: steady
Dose: 70 mg, 1 times / day
Sources:
unhealthy, adult
n = 79
Health Status: unhealthy
Condition: Attention-Deficit/Hyperactivity Disorder
Age Group: adult
Population Size: 79
Sources:
Headache below serious, 20 patients
70 mg 1 times / day steady, oral (max)
Dose: 70 mg, 1 times / day
Route: oral
Route: steady
Dose: 70 mg, 1 times / day
Sources:
unhealthy, adult
n = 79
Health Status: unhealthy
Condition: Attention-Deficit/Hyperactivity Disorder
Age Group: adult
Population Size: 79
Sources:
Dry mouth below serious, 25 patients
70 mg 1 times / day steady, oral (max)
Dose: 70 mg, 1 times / day
Route: oral
Route: steady
Dose: 70 mg, 1 times / day
Sources:
unhealthy, adult
n = 79
Health Status: unhealthy
Condition: Attention-Deficit/Hyperactivity Disorder
Age Group: adult
Population Size: 79
Sources:
Decreased appetite below serious, 26 patients
70 mg 1 times / day steady, oral (max)
Dose: 70 mg, 1 times / day
Route: oral
Route: steady
Dose: 70 mg, 1 times / day
Sources:
unhealthy, adult
n = 79
Health Status: unhealthy
Condition: Attention-Deficit/Hyperactivity Disorder
Age Group: adult
Population Size: 79
Sources:
Anorexia below serious, 4 patients
70 mg 1 times / day steady, oral (max)
Dose: 70 mg, 1 times / day
Route: oral
Route: steady
Dose: 70 mg, 1 times / day
Sources:
unhealthy, adult
n = 79
Health Status: unhealthy
Condition: Attention-Deficit/Hyperactivity Disorder
Age Group: adult
Population Size: 79
Sources:
Heart rate increased below serious, 4 patients
70 mg 1 times / day steady, oral (max)
Dose: 70 mg, 1 times / day
Route: oral
Route: steady
Dose: 70 mg, 1 times / day
Sources:
unhealthy, adult
n = 79
Health Status: unhealthy
Condition: Attention-Deficit/Hyperactivity Disorder
Age Group: adult
Population Size: 79
Sources:
Libido decreased below serious, 4 patients
70 mg 1 times / day steady, oral (max)
Dose: 70 mg, 1 times / day
Route: oral
Route: steady
Dose: 70 mg, 1 times / day
Sources:
unhealthy, adult
n = 79
Health Status: unhealthy
Condition: Attention-Deficit/Hyperactivity Disorder
Age Group: adult
Population Size: 79
Sources:
Hyperhidrosis below serious, 5 patients
70 mg 1 times / day steady, oral (max)
Dose: 70 mg, 1 times / day
Route: oral
Route: steady
Dose: 70 mg, 1 times / day
Sources:
unhealthy, adult
n = 79
Health Status: unhealthy
Condition: Attention-Deficit/Hyperactivity Disorder
Age Group: adult
Population Size: 79
Sources:
Upper respiratory tract infection below serious, 5 patients
70 mg 1 times / day steady, oral (max)
Dose: 70 mg, 1 times / day
Route: oral
Route: steady
Dose: 70 mg, 1 times / day
Sources:
unhealthy, adult
n = 79
Health Status: unhealthy
Condition: Attention-Deficit/Hyperactivity Disorder
Age Group: adult
Population Size: 79
Sources:
Diarrhea below serious, 6 patients
70 mg 1 times / day steady, oral (max)
Dose: 70 mg, 1 times / day
Route: oral
Route: steady
Dose: 70 mg, 1 times / day
Sources:
unhealthy, adult
n = 79
Health Status: unhealthy
Condition: Attention-Deficit/Hyperactivity Disorder
Age Group: adult
Population Size: 79
Sources:
Fatigue below serious, 6 patients
70 mg 1 times / day steady, oral (max)
Dose: 70 mg, 1 times / day
Route: oral
Route: steady
Dose: 70 mg, 1 times / day
Sources:
unhealthy, adult
n = 79
Health Status: unhealthy
Condition: Attention-Deficit/Hyperactivity Disorder
Age Group: adult
Population Size: 79
Sources:
Initial insomnia below serious, 8 patients
70 mg 1 times / day steady, oral (max)
Dose: 70 mg, 1 times / day
Route: oral
Route: steady
Dose: 70 mg, 1 times / day
Sources:
unhealthy, adult
n = 79
Health Status: unhealthy
Condition: Attention-Deficit/Hyperactivity Disorder
Age Group: adult
Population Size: 79
Sources:
Irritability below serious, 8 patients
70 mg 1 times / day steady, oral (max)
Dose: 70 mg, 1 times / day
Route: oral
Route: steady
Dose: 70 mg, 1 times / day
Sources:
unhealthy, adult
n = 79
Health Status: unhealthy
Condition: Attention-Deficit/Hyperactivity Disorder
Age Group: adult
Population Size: 79
Sources:
Weight decreased below serious, 8 patients
70 mg 1 times / day steady, oral (max)
Dose: 70 mg, 1 times / day
Route: oral
Route: steady
Dose: 70 mg, 1 times / day
Sources:
unhealthy, adult
n = 79
Health Status: unhealthy
Condition: Attention-Deficit/Hyperactivity Disorder
Age Group: adult
Population Size: 79
Sources:
Abuse Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder|Binge Eating Disorder
Sources: Page: p.1
Blood pressure increased Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder|Binge Eating Disorder
Sources: Page: p.1
Dependence Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder|Binge Eating Disorder
Sources: Page: p.1
Growth suppression Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder|Binge Eating Disorder
Sources: Page: p.1
Heart rate increased Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder|Binge Eating Disorder
Sources: Page: p.1
Manic symptom Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder|Binge Eating Disorder
Sources: Page: p.1
Psychiatric symptom NOS Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder|Binge Eating Disorder
Sources: Page: p.1
Psychotic symptom Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder|Binge Eating Disorder
Sources: Page: p.1
Raynaud's phenomenon Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder|Binge Eating Disorder
Sources: Page: p.1
Serotonin syndrome Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder|Binge Eating Disorder
Sources: Page: p.1
Vascular disorders Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder|Binge Eating Disorder
Sources: Page: p.1
Cardiovascular disorder (NOS) grade 3-5
Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder|Binge Eating Disorder
Sources: Page: p.1
Myocardial infarction serious
Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder|Binge Eating Disorder
Sources: Page: p.1
Stroke serious
Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder|Binge Eating Disorder
Sources: Page: p.1
Insomnia below serious, 10 patients
50 mg 1 times / day steady, oral (max)
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy
n = 28
Health Status: unhealthy
Condition: Major Depressive Disorder
Population Size: 28
Sources:
Diaphoresis below serious, 2 patients
50 mg 1 times / day steady, oral (max)
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy
n = 28
Health Status: unhealthy
Condition: Major Depressive Disorder
Population Size: 28
Sources:
Libido decreased below serious, 2 patients
50 mg 1 times / day steady, oral (max)
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy
n = 28
Health Status: unhealthy
Condition: Major Depressive Disorder
Population Size: 28
Sources:
Paresthesia below serious, 2 patients
50 mg 1 times / day steady, oral (max)
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy
n = 28
Health Status: unhealthy
Condition: Major Depressive Disorder
Population Size: 28
Sources:
Tinnitus below serious, 2 patients
50 mg 1 times / day steady, oral (max)
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy
n = 28
Health Status: unhealthy
Condition: Major Depressive Disorder
Population Size: 28
Sources:
Irritability below serious, 3 patients
50 mg 1 times / day steady, oral (max)
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy
n = 28
Health Status: unhealthy
Condition: Major Depressive Disorder
Population Size: 28
Sources:
Tachycardia below serious, 3 patients
50 mg 1 times / day steady, oral (max)
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy
n = 28
Health Status: unhealthy
Condition: Major Depressive Disorder
Population Size: 28
Sources:
Muscle tension below serious, 4 patients
50 mg 1 times / day steady, oral (max)
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy
n = 28
Health Status: unhealthy
Condition: Major Depressive Disorder
Population Size: 28
Sources:
Dry mouth below serious, 7 patients
50 mg 1 times / day steady, oral (max)
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy
n = 28
Health Status: unhealthy
Condition: Major Depressive Disorder
Population Size: 28
Sources:
Decreased appetite below serious, 8 patients
50 mg 1 times / day steady, oral (max)
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy
n = 28
Health Status: unhealthy
Condition: Major Depressive Disorder
Population Size: 28
Sources:
Overview

Overview

OverviewOther

Other InhibitorOther SubstrateOther Inducer





Drug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
likely
likely (co-administration study)
Comment: Amphetamines and amphetamine derivatives are known to be metabolized, to some degree, by cytochrome P450 2D6 (CYP2D6) and display minor inhibition of CYP2D6 metabolism; concomitant use of DEXEDRINE and CYP2D6 inhibitors may increase the exposure of DEXEDRINE;
Page: 4.0
no
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Agonist and antagonist activity of low efficacy D2 dopamine receptor agonists in rats discriminating d-amphetamine from saline.
1992 Dec
Psychostimulants, adult attention deficit hyperactivity disorder and morbid jealousy.
2000 Feb
Dopaminergic mRNA expression in the intact substantia nigra of unilaterally 6-OHDA-lesioned and grafted rats: an in situ hybridization study.
2001
No functional effects of embryonic neuronal grafts on motor deficits in a 3-nitropropionic acid rat model of advanced striatonigral degeneration (multiple system atrophy).
2001
The purinergic P2 receptor antagonist pyridoxalphosphate-6-azophenyl-2'4'-disulphonic acid prevents both the acute locomotor effects of amphetamine and the behavioural sensitization caused by repeated amphetamine injections in rats.
2001
Determination of amphetamine in dog plasma by gas chromatography with mass selective detection.
2001 Apr
A nitric oxide-dopamine link pathway in organum vasculosum laminae terminalis of rat brain exerts control over blood pressure.
2001 Apr
Effect of 6-hydroxydopamine or repeated amphetamine treatment on mesencephalic mRNA levels for AMPA glutamate receptor subunits in the rat.
2001 Apr 20
Interleukin-2 potentiates novelty- and GBR 12909-induced exploratory activity.
2001 Apr 27
Tyrosine improves behavioral and neurochemical deficits caused by cold exposure.
2001 Feb
Differences in locomotor response to an inescapable novel environment predict sensitivity to aversive effects of amphetamine.
2001 Feb
Effects of acute D-amphetamine and ketamine on the performance of rats in a serial negative patterning procedure.
2001 Feb
The D3R partial agonist, BP 897, attenuates the discriminative stimulus effects of cocaine and D-amphetamine and is not self-administered.
2001 Feb
Chronic inositol increases striatal D(2) receptors but does not modify dexamphetamine-induced motor behavior. Relevance to obsessive-compulsive disorder.
2001 Feb
Transcranial magnetic stimulation in an amphetamine hyperactivity model of mania.
2001 Feb
Comparison of the effects of infant handling, isolation, and nonhandling on acoustic startle, prepulse inhibition, locomotion, and HPA activity in the adult rat.
2001 Feb
Conditioned activity to amphetamine in transgenic mice expressing an antisense RNA against the glucocorticoid receptor.
2001 Feb
Relevance of pharmacokinetic parameters in animal models of methamphetamine abuse.
2001 Feb
Regional distribution of methamphetamine in autopsied brain of chronic human methamphetamine users.
2001 Feb 15
Neuroprotective effect of vitamin E on the early model of Parkinson's disease in rat: behavioral and histochemical evidence.
2001 Feb 16
Analysis of benzphetamine and its metabolites in rat urine by liquid chromatography-electrospray ionization mass spectrometry.
2001 Feb 25
Striatal dopamine sensitization to D-amphetamine in periadolescent but not in adult rats.
2001 Jan
Acute hydrocortisone administration does not affect subjective responses to d-amphetamine in humans.
2001 Jan
Distinct contributions of glutamate and dopamine receptors to temporal aspects of rodent working memory using a clinically relevant task.
2001 Jan
Modification of d-amphetamine-induced responses by baclofen in rats.
2001 Jan
[Analysis of the striato-pallidal interactions in regulation of avoidance behavior].
2001 Jan
Role of mitochondrial dysfunction and dopamine-dependent oxidative stress in amphetamine-induced toxicity.
2001 Jan
Influence of time in culture and BDNF pretreatment on survival and function of grafted embryonic rat ventral mesencephalon in the 6-OHDA rat model of Parkinson's disease.
2001 Jan
What is a "low dose" of d-amphetamine for inducing behavioral effects in laboratory rats?
2001 Jan 1
Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria.
2001 Jan 15
Environmental novelty differentially affects c-fos mRNA expression induced by amphetamine or cocaine in subregions of the bed nucleus of the stria terminalis and amygdala.
2001 Jan 15
Significance of glutamate and dopamine neurons in the ventral pallidum in the expression of behavioral sensitization to amphetamine.
2001 Jan 19
Fetal intra-nigral ventral mesencephalon and kidney tissue bridge transplantation restores the nigrostriatal dopamine pathway in hemi-parkinsonian rats.
2001 Jan 19
Behavioural and anti-psychotic effects of Ca2+ channel blockers in rhesus monkey.
2001 Jan 26
Differential sensitivity to lithium's reversal of amphetamine-induced open-field activity in two inbred strains of mice.
2001 Jan 8
Cannabinoid CB1 receptor knockout mice fail to self-administer morphine but not other drugs of abuse.
2001 Jan 8
Computer-aided screening for hallucinogenic and stimulant amphetamines with gas chromatography-Fourier transform infrared spectroscopy (GC-FTIR).
2001 Jan-Feb
The weaver mutant mouse: a model to study the ontogeny of dopamine transmission systems and their role in drug addiction.
2001 Jun
Effects of d-amphetamine on the performance of rats in an animal analogue of the A-X continuous performance test.
2001 Mar
Amphetamine selectively blocks inhibitory glutamate transmission in dopamine neurons.
2001 Mar
Seizure activity and hyperthermia potentiate the increases in dopamine and serotonin extracellular levels in the amygdala during exposure to d-amphetamine.
2001 Mar
Expression of sensitization to amphetamine and dynamics of dopamine neurotransmission in different laminae of the rat medial prefrontal cortex.
2001 Mar
Previous exposure to amphetamine enhances the subsequent locomotor response to a D1 dopamine receptor agonist when glutamate reuptake is inhibited.
2001 Mar 1
Dopaminergic role in stimulant-induced wakefulness.
2001 Mar 1
Dissociations between the effects of intra-accumbens administration of amphetamine and exposure to a novel environment on accumbens dopamine and cortical acetylcholine release.
2001 Mar 16
Serotonin transporter localization in the hamster suprachiasmatic nucleus.
2001 Mar 2
Amphetamine normalizes the electrical activity of dopamine neurons in the ventral tegmental area following prenatal ethanol exposure.
2001 May
Cocaine and amphetamine increase extracellular dopamine in the nucleus accumbens of mice lacking the dopamine transporter gene.
2001 May 1
Genes in drug abuse.
2001 May 1
Post-training injections of catecholaminergic drugs do not modulate fear conditioning in rats and mice.
2001 May 4
Patents

Sample Use Guides

Usual dose is 5 to 60 mg per day in divided doses, depending on the individual patient response. Narcolepsy seldom occurs in children under 12 years of age; however, when it does, DEXEDRINE may be used. The suggested initial dose for patients aged 6 to 12 is 5 mg daily; daily dose may be raised in increments of 5 mg at weekly intervals until an optimal response is obtained. In patients 12 years of age and older, start with 10 mg daily; daily dosage may be raised in increments of 10 mg at weekly intervals until an optimal response is obtained. If bothersome adverse reactions appear (e.g., insomnia or anorexia), dosage should be reduced. SPANSULE capsules may be used for once-a-day dosage wherever appropriate.
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment: The action of several concentrations of d-amphetamine on the NADH-tetrazolium reductase histochemical reaction has been studied in several nervous regions of rats. The facts observed have demonstrated that d-amphetamine increases the intensity of the histochemical reaction by its action on NADH-oxido-reductase activity in all nervous regions studied.
Unknown
Substance Class Chemical
Created
by admin
on Wed Jul 05 22:43:37 UTC 2023
Edited
by admin
on Wed Jul 05 22:43:37 UTC 2023
Record UNII
TZ47U051FI
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DEXTROAMPHETAMINE
HSDB   MI   USAN   VANDF  
USAN  
Official Name English
AMPHETAMINE, D-
Common Name English
dexamfetamine [INN]
Common Name English
DEXAMFETAMINE
INN   WHO-DD  
INN  
Official Name English
AMFETAMINE, (S)-
Common Name English
DEXIDRINE
Common Name English
DEXTROAMPHETAMINE [USAN]
Common Name English
NSC-73713
Code English
DEXTROAMPHETAMINE [HSDB]
Common Name English
(S)-1-PHENYL-2-AMINOPROPANE
Systematic Name English
(+)-.ALPHA.-METHYLPHENETHYLAMINE
Systematic Name English
Dexamfetamine [WHO-DD]
Common Name English
DEXAMPHETAMINE
Common Name English
(+)-(S)-AMPHETAMINE
Systematic Name English
BENZENEETHANAMINE, .ALPHA.-METHYL-, (S)-
Systematic Name English
DEXTROAMPHETAMINE [MI]
Common Name English
D-AMPHETAMINE
Common Name English
XELSTRYM
Brand Name English
DEXTROAMPHETAMINE [VANDF]
Common Name English
Classification Tree Code System Code
WHO-VATC QN06BA02
Created by admin on Wed Jul 05 22:43:37 UTC 2023 , Edited by admin on Wed Jul 05 22:43:37 UTC 2023
CFR 21 CFR 310.502
Created by admin on Wed Jul 05 22:43:37 UTC 2023 , Edited by admin on Wed Jul 05 22:43:37 UTC 2023
WHO-ATC N06BA02
Created by admin on Wed Jul 05 22:43:37 UTC 2023 , Edited by admin on Wed Jul 05 22:43:37 UTC 2023
NDF-RT N0000175739
Created by admin on Wed Jul 05 22:43:37 UTC 2023 , Edited by admin on Wed Jul 05 22:43:37 UTC 2023
NCI_THESAURUS C47795
Created by admin on Wed Jul 05 22:43:37 UTC 2023 , Edited by admin on Wed Jul 05 22:43:37 UTC 2023
EPA PESTICIDE CODE 600005
Created by admin on Wed Jul 05 22:43:37 UTC 2023 , Edited by admin on Wed Jul 05 22:43:37 UTC 2023
LIVERTOX 293
Created by admin on Wed Jul 05 22:43:37 UTC 2023 , Edited by admin on Wed Jul 05 22:43:37 UTC 2023
NDF-RT N0000175729
Created by admin on Wed Jul 05 22:43:37 UTC 2023 , Edited by admin on Wed Jul 05 22:43:37 UTC 2023
Code System Code Type Description
RXCUI
3288
Created by admin on Wed Jul 05 22:43:37 UTC 2023 , Edited by admin on Wed Jul 05 22:43:37 UTC 2023
PRIMARY RxNorm
EPA CompTox
DTXSID8022907
Created by admin on Wed Jul 05 22:43:37 UTC 2023 , Edited by admin on Wed Jul 05 22:43:37 UTC 2023
PRIMARY
DAILYMED
TZ47U051FI
Created by admin on Wed Jul 05 22:43:37 UTC 2023 , Edited by admin on Wed Jul 05 22:43:37 UTC 2023
PRIMARY
CAS
51-64-9
Created by admin on Wed Jul 05 22:43:37 UTC 2023 , Edited by admin on Wed Jul 05 22:43:37 UTC 2023
PRIMARY
NSC
73713
Created by admin on Wed Jul 05 22:43:37 UTC 2023 , Edited by admin on Wed Jul 05 22:43:37 UTC 2023
PRIMARY
CHEBI
4469
Created by admin on Wed Jul 05 22:43:37 UTC 2023 , Edited by admin on Wed Jul 05 22:43:37 UTC 2023
PRIMARY
INN
1430
Created by admin on Wed Jul 05 22:43:37 UTC 2023 , Edited by admin on Wed Jul 05 22:43:37 UTC 2023
PRIMARY
DRUG CENTRAL
841
Created by admin on Wed Jul 05 22:43:37 UTC 2023 , Edited by admin on Wed Jul 05 22:43:37 UTC 2023
PRIMARY
ChEMBL
CHEMBL612
Created by admin on Wed Jul 05 22:43:37 UTC 2023 , Edited by admin on Wed Jul 05 22:43:37 UTC 2023
PRIMARY
FDA UNII
TZ47U051FI
Created by admin on Wed Jul 05 22:43:37 UTC 2023 , Edited by admin on Wed Jul 05 22:43:37 UTC 2023
PRIMARY
LACTMED
Dextroamphetamine
Created by admin on Wed Jul 05 22:43:37 UTC 2023 , Edited by admin on Wed Jul 05 22:43:37 UTC 2023
PRIMARY
EVMPD
SUB07019MIG
Created by admin on Wed Jul 05 22:43:37 UTC 2023 , Edited by admin on Wed Jul 05 22:43:37 UTC 2023
PRIMARY
SMS_ID
100000088421
Created by admin on Wed Jul 05 22:43:37 UTC 2023 , Edited by admin on Wed Jul 05 22:43:37 UTC 2023
PRIMARY
DRUG BANK
DB01576
Created by admin on Wed Jul 05 22:43:37 UTC 2023 , Edited by admin on Wed Jul 05 22:43:37 UTC 2023
PRIMARY
WIKIPEDIA
DEXTROAMPHETAMINE
Created by admin on Wed Jul 05 22:43:37 UTC 2023 , Edited by admin on Wed Jul 05 22:43:37 UTC 2023
PRIMARY
PUBCHEM
5826
Created by admin on Wed Jul 05 22:43:37 UTC 2023 , Edited by admin on Wed Jul 05 22:43:37 UTC 2023
PRIMARY
ECHA (EC/EINECS)
200-112-1
Created by admin on Wed Jul 05 22:43:37 UTC 2023 , Edited by admin on Wed Jul 05 22:43:37 UTC 2023
PRIMARY
MERCK INDEX
M4226
Created by admin on Wed Jul 05 22:43:37 UTC 2023 , Edited by admin on Wed Jul 05 22:43:37 UTC 2023
PRIMARY Merck Index
IUPHAR
2147
Created by admin on Wed Jul 05 22:43:37 UTC 2023 , Edited by admin on Wed Jul 05 22:43:37 UTC 2023
PRIMARY
MESH
D003913
Created by admin on Wed Jul 05 22:43:37 UTC 2023 , Edited by admin on Wed Jul 05 22:43:37 UTC 2023
PRIMARY
NCI_THESAURUS
C28981
Created by admin on Wed Jul 05 22:43:37 UTC 2023 , Edited by admin on Wed Jul 05 22:43:37 UTC 2023
PRIMARY
HSDB
3055
Created by admin on Wed Jul 05 22:43:37 UTC 2023 , Edited by admin on Wed Jul 05 22:43:37 UTC 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
TRANSPORTER -> INHIBITOR
TRANSPORTER -> INHIBITOR
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
TRANSPORTER -> INHIBITOR
SALT/SOLVATE -> PARENT
Related Record Type Details
PRODRUG -> METABOLITE ACTIVE
METABOLITE -> PARENT
METABOLITE -> PARENT
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Tmax PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC Adult
PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC ORAL ADMINISTRATION